Tags

Type your tag names separated by a space and hit enter

Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.
Lancet Infect Dis. 2020 Aug; 20(8):e181-e191.LI

Abstract

Progressive antimicrobial resistance in Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis has created a pressing need for treatment optimisations for sexually transmitted infections (STIs). In this Review, we aim to highlight urgent needs in global STI management, including: (1) improved surveillance to monitor antimicrobial resistance and clinical outcomes; (2) systematic pharmacokinetic and pharmacodynamic evaluations to ensure resistance suppression and bacterial eradication at all sites of infection; (3) development of novel, affordable antimicrobials; and (4) advancements in new molecular and point-of-care tests to detect antimicrobial resistance determinants. Antimicrobial resistance among STIs is a global public health crisis. Continuous efforts to develop novel antimicrobials will be essential, in addition to other public health interventions to reduce the global STI burden. Apart from prevention through safer sexual practices, the development of STI vaccines to prevent transmission is a crucial research priority.

Authors+Show Affiliations

Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. Electronic address: idrod@med.unc.edu.Department of Medicine, Wake Forest University, Winston Salem, NC, USA; Division of Sexually Transmitted Diseases Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.Department of Medicine, University of Washington, Seattle, WA, USA.Global HIV, Hepatitis and Sexually Transmitted Infections Programme, WHO, Geneva, Switzerland.Division of Sexually Transmitted Diseases Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA; Department of Medicine, Emory University, Atlanta, GA, USA.Department of Medicine, University of Alabama, Birmingham, AL, USA.Sexual Health Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.Institute for Therapeutic Innovation, University of Florida, Orlando, FL, USA.WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections and the Swedish Reference Laboratory for STIs, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32569625

Citation

Seña, Arlene C., et al. "Optimising Treatments for Sexually Transmitted Infections: Surveillance, Pharmacokinetics and Pharmacodynamics, Therapeutic Strategies, and Molecular Resistance Prediction." The Lancet. Infectious Diseases, vol. 20, no. 8, 2020, pp. e181-e191.
Seña AC, Bachmann L, Johnston C, et al. Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. Lancet Infect Dis. 2020;20(8):e181-e191.
Seña, A. C., Bachmann, L., Johnston, C., Wi, T., Workowski, K., Hook, E. W., Hocking, J. S., Drusano, G., & Unemo, M. (2020). Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. The Lancet. Infectious Diseases, 20(8), e181-e191. https://doi.org/10.1016/S1473-3099(20)30171-7
Seña AC, et al. Optimising Treatments for Sexually Transmitted Infections: Surveillance, Pharmacokinetics and Pharmacodynamics, Therapeutic Strategies, and Molecular Resistance Prediction. Lancet Infect Dis. 2020;20(8):e181-e191. PubMed PMID: 32569625.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. AU - Seña,Arlene C, AU - Bachmann,Laura, AU - Johnston,Christine, AU - Wi,Teodora, AU - Workowski,Kimberly, AU - Hook,Edward W,3rd AU - Hocking,Jane S, AU - Drusano,George, AU - Unemo,Magnus, Y1 - 2020/06/19/ PY - 2019/03/24/received PY - 2020/02/12/revised PY - 2020/03/05/accepted PY - 2020/6/23/pubmed PY - 2020/6/23/medline PY - 2020/6/23/entrez SP - e181 EP - e191 JF - The Lancet. Infectious diseases JO - Lancet Infect Dis VL - 20 IS - 8 N2 - Progressive antimicrobial resistance in Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis has created a pressing need for treatment optimisations for sexually transmitted infections (STIs). In this Review, we aim to highlight urgent needs in global STI management, including: (1) improved surveillance to monitor antimicrobial resistance and clinical outcomes; (2) systematic pharmacokinetic and pharmacodynamic evaluations to ensure resistance suppression and bacterial eradication at all sites of infection; (3) development of novel, affordable antimicrobials; and (4) advancements in new molecular and point-of-care tests to detect antimicrobial resistance determinants. Antimicrobial resistance among STIs is a global public health crisis. Continuous efforts to develop novel antimicrobials will be essential, in addition to other public health interventions to reduce the global STI burden. Apart from prevention through safer sexual practices, the development of STI vaccines to prevent transmission is a crucial research priority. SN - 1474-4457 UR - https://www.unboundmedicine.com/medline/citation/32569625/Optimising_treatments_for_sexually_transmitted_infections:_surveillance,_pharmacokinetics_and_pharmacodynamics,_therapeutic_strategies,_and_molecular_resistance_prediction L2 - https://linkinghub.elsevier.com/retrieve/pii/S1473-3099(20)30171-7 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.